Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director · Chief Executive Officer | August 17, 2026 | August 19, 2026 |
| CONMED CorpCNMD · Entity 4691 | Director | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,590 |
Reported balance
After 2026-08-17 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-08-17 · Grant · Acquired 57,590 · Balance 57,590 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 93,582 |
Reported balance
After 2026-08-17 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-08-17 · Grant · Acquired 93,582 · Balance 93,582 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13: 93,582 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,544 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 8,544 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10: 8,544 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,569 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 23,569 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11: 11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. |
| Common StockSEC Table I · non-derivative | Direct | 82,762 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 82,762 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 115,724 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 115,724 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 25,944 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 25,944 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 28,940 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 28,940 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 1,492 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,492 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 29,391 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 29,391 F2: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.83 · Expires 2030-11-01 | Direct | 38,252 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 38,252 F3: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.54 · Expires 2031-02-01 | Direct | 1,621 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 1,621 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.54 · Expires 2031-02-01 | Direct | 51,890 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 51,890 F4: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 69,061 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 69,061 F5: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 90,441 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 90,441 F6: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 51,261 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 51,261 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 70,708 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 70,708 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
F3: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
F4: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
F5: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
F6: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F8: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: 8,544 restricted stock units vest on 8/15/2027.
F11: 11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
F12: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029.
F13: 93,582 restricted stock units vest on 8/17/2029.
CONMED Corp
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 500 · Balance 500 |
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-09-08 | Direct | 0 |
Reported balance
After 2026-09-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-08 · Exercise / conversion · Disposed 500 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 25,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015385 · form4.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,630 Underlying: Common Stock · 25,630 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. F11 · derivative.expiration_date: 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 51,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015385 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,261 Underlying: Common Stock · 51,261 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $37.70 | $0.00 |
DisclosureSEC source: 0001062993-24-014366 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,392 Underlying: Common Stock · 14,000 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 9,479 | $81.97 | $776,993.63 |
DisclosureSEC source: 0001062993-24-014366 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,942 Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 14,000 | $37.70 | $527,800.00 |
DisclosureSEC source: 0001062993-24-014366 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 51,890 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0001062993-24-002018 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,890 Underlying: Common Stock · 51,890 shares Expires 2031-02-01 F11 · derivative.exercise_date: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 25,945 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0001062993-24-002018 · form4.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,945 Underlying: Common Stock · 25,945 shares Expires 2031-02-01 F8 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:33 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 9,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-002018 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,423 Underlying: Common Stock · 9,423 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F8 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 38,252 | $0.00 Strike: $52.83 | $0.00 |
DisclosureSEC source: 0001062993-23-020118 · form4.xml · derivative · entry 16 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,252 Underlying: Common Stock · 38,252 shares Expires 2030-11-01 F11 · derivative.exercise_date: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 14,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020118 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,421 F1 · shares: Represents 14,196 shares of restricted stock for which risks of forfeiture lapse as to 4,732 shares on each of 11/1/2024, 11/1/2025 and 11/1/2026. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 20:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,100 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0001062993-23-017156 · form4.xml · derivative · entry 4 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,536 Underlying: Common Stock · 2,100 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 20:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,100 | $47.60 | $99,960.00 |
DisclosureSEC source: 0001062993-23-017156 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 29,391 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016714 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,391 Underlying: Common Stock · 29,391 shares Expires 2030-08-15 F10 · derivative.exercise_date: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 22,043 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016714 · form4.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,043 Underlying: Common Stock · 22,043 shares Expires 2030-08-15 F9 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 8,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016714 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,191 Underlying: Common Stock · 8,191 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:13 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 23,881 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022601 · form4a.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,881 Underlying: Common Stock · 23,881 shares Expires 2030-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:13 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 8,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022601 · form4a.xml · derivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,873 Underlying: Common Stock · 8,873 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 8,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016036 · form4.xml · derivative · entry 10 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/5/2023, the Board of Directors certified vesting of 8,060 performance RSUs. F3 · derivative.expiration_date: On 8/5/2023, the Board of Directors certified vesting of 8,060 performance RSUs. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 4,139 | $82.17 | $340,101.63 |
DisclosureSEC source: 0001062993-23-016036 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,125 Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 8,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016036 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 663 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001437749-22-021367 · rdgdoc.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,848 Underlying: Common Stock · 663 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 663 | $150.78 | $99,967.14 |
DisclosureSEC source: 0001437749-22-021367 · rdgdoc.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 7,235 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008784 · form4-08172022_020800.xml · derivative · entry 4 Kelderman Kim · CIK 0001739054 · PRES. DIAGNOSTICS & GENOM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,235 Underlying: Common Stock · 7,235 shares Expires 2029-08-15 F3 · derivative.exercise_date: Options to purchase 1,809 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 1,808 shares vest on 8/15/2025. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 5,426 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008784 · form4-08172022_020800.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · PRES. DIAGNOSTICS & GENOM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,426 Underlying: Common Stock · 5,426 shares Expires 2029-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008784 · form4-08172022_020800.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · PRES. DIAGNOSTICS & GENOM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,746 Underlying: Common Stock · 1,746 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019667 · rdgdoc.xml · derivative · entry 6 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/7/2022, the Board of Directors certified vesting of 2,363 performance RSUs. F3 · derivative.expiration_date: On 8/7/2022, the Board of Directors certified vesting of 2,363 performance RSUs. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,214 | $382.97 | $464,925.58 |
DisclosureSEC source: 0001437749-22-019667 · rdgdoc.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,138 Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019667 · rdgdoc.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,989 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001437749-22-003021 · rdgdoc.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,511 Underlying: Common Stock · 1,989 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options to purchase 2,500 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,989 | $150.78 | $299,901.42 |
DisclosureSEC source: 0001437749-22-003021 · rdgdoc.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001437749-21-027339 · rdgdoc.xml · derivative · entry 4 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,152 Underlying: Common Stock · 500 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options to purchase 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 400 | $505.78 | $202,313.00 |
DisclosureSEC source: 0001437749-21-027339 · rdgdoc.xml · nonDerivative · entry 3 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.62 to $506.17, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $503.76 | $50,376.00 |
DisclosureSEC source: 0001437749-21-027339 · rdgdoc.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 500 | $150.78 | $75,390.00 |
DisclosureSEC source: 0001437749-21-027339 · rdgdoc.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 20:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 822 | $529.04 | $434,870.88 |
DisclosureSEC source: 0000914190-21-000374 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · derivative · entry 5 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F4 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 869 | $481.82 | $418,701.58 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822 Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 6,486 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,486 Underlying: Common Stock · 6,486 shares Expires 2028-08-06 F13 · derivative.exercise_date: Options to purchase 1,622 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,621 shares vest on each of 8/6/2024 and 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 4,864 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,864 Underlying: Common Stock · 4,864 shares Expires 2028-08-06 F12 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,245 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · derivative · entry 16 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,245 Underlying: Common Stock · 1,245 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F12 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 811 | $433.00 | $351,163.00 |
DisclosureSEC source: 0000914190-21-000183 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 845 | $424.00 | $358,280.00 |
DisclosureSEC source: 0000914190-21-000166 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811 Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000134 · edgar.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 1,667 restricted stock units vest on 5/1/2021. F2 · derivative.expiration_date: 1,667 restricted stock units vest on 5/1/2021. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 856 | $427.49 | $365,931.44 |
DisclosureSEC source: 0000914190-21-000134 · edgar.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,656 Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:54 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-21-000134 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 823 | $388.45 | $319,694.35 |
DisclosureSEC source: 0000914190-21-000039 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 15 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F12 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 14 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F11 · derivative.exercise_date: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 11,988 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 13 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,988 Underlying: Common Stock · 11,988 shares Expires 2027-08-05 F10 · derivative.exercise_date: Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.